Genesis Private Wealth LLC Acquires New Holdings in AstraZeneca PLC (NASDAQ:AZN)

Genesis Private Wealth LLC bought a new position in shares of AstraZeneca PLC (NASDAQ:AZN) during the fourth quarter, HoldingsChannel reports. The fund bought 3,205 shares of the company’s stock, valued at approximately $210,000.

Other large investors also recently modified their holdings of the company. Martin Investment Management LLC grew its holdings in AstraZeneca by 2.8% during the 3rd quarter. Martin Investment Management LLC now owns 284,204 shares of the company’s stock worth $22,571,000 after acquiring an additional 7,615 shares during the last quarter. Nordea Investment Management AB bought a new stake in shares of AstraZeneca in the fourth quarter worth $754,000. Integrated Advisors Network LLC increased its holdings in AstraZeneca by 46.6% in the third quarter. Integrated Advisors Network LLC now owns 43,610 shares of the company’s stock valued at $3,398,000 after purchasing an additional 13,860 shares during the period. Oak Ridge Investments LLC raised its position in AstraZeneca by 5.4% during the 4th quarter. Oak Ridge Investments LLC now owns 143,973 shares of the company’s stock worth $9,433,000 after purchasing an additional 7,341 shares during the last quarter. Finally, Creative Planning lifted its holdings in AstraZeneca by 8.0% during the 3rd quarter. Creative Planning now owns 224,751 shares of the company’s stock worth $17,510,000 after buying an additional 16,692 shares during the period. 20.35% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on AZN shares. UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a research report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, AstraZeneca currently has an average rating of “Buy” and a consensus target price of $89.75.

AstraZeneca Price Performance

Shares of AZN opened at $68.20 on Thursday. The firm has a market cap of $211.49 billion, a PE ratio of 32.63, a price-to-earnings-growth ratio of 1.13 and a beta of 0.46. AstraZeneca PLC has a 52-week low of $60.47 and a 52-week high of $87.68. The business’s 50 day moving average price is $66.20 and its two-hundred day moving average price is $74.32. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.71 and a current ratio of 0.93.

AstraZeneca (NASDAQ:AZN) last released its earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The company had revenue of $13.57 billion for the quarter, compared to the consensus estimate of $13.08 billion. During the same quarter in the previous year, the company earned $0.87 EPS. AstraZeneca’s quarterly revenue was up 18.0% compared to the same quarter last year. On average, equities analysts anticipate that AstraZeneca PLC will post 4.12 EPS for the current year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.